CureVac fails in COVID-19 vaccine trial with 47% efficacy
By Ouyang Xueyan | chinadaily.com.cn
Updated: 2021-06-18 00:04
Share - WeChat
German biotech CureVac's COVID-19 vaccine has come out of a late-stage trial with 47 percent efficacy but the health ministry has said this will not impact the country's vaccination rollout.
